ORMP
Oramed Pharmaceuticals Inc
4.50$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -441.4% | – | – | – | – | – | – | – | – | |
| – | -1.9% | +5.7% | -3.6% | -3.7% | -40.4% | -3.2% | +0.0% | +3.3% | -3.2% | +0.0% | +3.3% | – | |
| – | +60.4% | -5.3% | -5.0% | -75.5% | +308.3% | +78.1% | -63.5% | -10.1% | +217.7% | -24.0% | -19.8% | – | |
| – | -123.5% | – | – | -24.9% | -98.3% | -5,923.2% | – | – | -93.4% | +1,105.4% | -75.4% | – | |
| – | -92.8% | 0.0% | -99.1% | +29,114.5% | +121.1% | -72.8% | +34.3% | -92.8% | +69,796.2% | -97.5% | -60.0% | – | |
| – | – | +2.3% | +212.1% | -135.9% | – | +49.8% | -332.9% | – | -104.3% | +1,057.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -4.7% | -99.2% | – | |
| – | – | – | – | – | -6.9% | – | – | +5.3% | +921.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -133.8% | -22.1% | +58.7% | -95.0% | -7.5% | -100.0% | – | +5.3% | +921.1% | +158.5% | -81.2% | – | |
| – | – | +165.4% | +595.1% | -164.4% | – | +63.2% | -392.2% | – | -117.1% | – | – | – | |
| – | – | – | – | -441.6% | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.